Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company whose news flow centers on cardiometabolic and neurological drug development, regulatory interactions and strategic collaborations. The company describes a mission of pioneering medicines that transform patients’ lives, supported by its Genome5000™ genomics platform, which identified more than 100 protein targets with therapeutic potential across multiple diseases.
News about Lexicon frequently highlights clinical data and conference presentations for sotagliflozin, an oral SGLT2 and SGLT1 inhibitor studied in approximately 20,000 patients with heart failure, diabetes and chronic kidney disease. Recent updates include results in heart failure with preserved ejection fraction, ongoing enrollment in the SONATA-HCM Phase 3 study for hypertrophic cardiomyopathy, and work toward regulatory pathways for ZYNQUISTA® in type 1 diabetes.
Investors and healthcare observers can also follow developments in pilavapadin (LX9211) for diabetic peripheral neuropathic pain, where Lexicon has reported Phase 2 and Phase 2b data and End-of-Phase 2 FDA discussions, as well as LX9851, a first-in-class ACSL5 inhibitor for obesity and cardiometabolic disorders licensed to Novo Nordisk. Company news includes licensing milestones, financial results, participation in major healthcare conferences and policy-focused initiatives such as a chronic pain roundtable and white paper on non-opioid treatments.
This LXRX news page aggregates these updates in one place, covering earnings releases, pipeline milestones, regulatory announcements, scientific publications and partnership news drawn from Lexicon’s public statements and SEC filings.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported its Q3 2021 financial results, showing negligible revenues compared to $6.6 million in Q3 2020, primarily due to the sale of XERMELO. R&D expenses decreased to $15.7 million from $40.1 million, while SG&A expenses fell to $7.3 million from $12 million. The net loss for Q3 2021 was $23.1 million, or $0.16 per share, contrasted with a net income of $82.6 million in the same quarter last year, which included a significant gain from the asset sale. Lexicon aims to submit a new drug application for sotagliflozin by year-end.
Lexicon Pharmaceuticals (LXRX) will announce its Q3 2021 financial results on November 3, 2021, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results and provide a business update. The call can be accessed via U.S. and international dial-in numbers. Lexicon focuses on pioneering medicines with a strong pipeline including drug candidates for neuropathic pain and diabetes. Forward-looking statements regarding the company’s financial health and drug development trajectory have been made but come with inherent risks.
On September 15, 2021, Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that President and CEO Lonnel Coats will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The presentation is scheduled for September 21, 2021, at 10:45 a.m. ET. A webcast of the event will be made available on Lexicon’s website, with an archived version accessible for two weeks following the event.
Lexicon is dedicated to pioneering medicines that transform patients' lives, focusing on therapeutic targets identified through its Genome5000™ program.
Lexicon Pharmaceuticals (Nasdaq: LXRX) supports the European Society of Cardiology's updated guidelines recommending SGLT inhibitors for heart failure treatment. This recommendation emphasizes the drugs' Class IA endorsement for reducing cardiovascular death and hospitalization risks in patients, especially those with diabetes. Notably, sotagliflozin, an investigational drug, was highlighted for its potential benefits before regulatory approval. Lexicon plans to file a New Drug Application with the FDA later this year for sotagliflozin as a heart failure therapy.
Lexicon Pharmaceuticals (LXRX) announced findings from the SOLOIST and SCORED trials for sotagliflozin at ESC Congress 2021. The trials revealed a 33% absolute reduction in cardiovascular risks for type 2 diabetes patients with acute heart failure and a 26% reduction in those with chronic kidney disease. Notably, the 400 mg dosage showed significant benefits in reducing heart failure events. The company plans to submit a New Drug Application for sotagliflozin, highlighting its potential as a treatment for heart failure in diabetes patients.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has appointed Craig Granowitz, M.D., Ph.D., as the new senior vice president and chief medical officer, effective August 2, 2021. Granowitz brings extensive pharmaceutical experience, previously serving as CMO at Amarin Corporation and holding senior roles at Merck & Co. He is expected to lead the medical affairs organization and oversee the development of Lexicon's drug pipeline, particularly sotagliflozin, aimed at treating heart failure in type 2 diabetes patients. He possesses a strong background in cardiovascular medicine, crucial for advancing Lexicon's therapeutic goals.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q2 2021 financial results, revealing a significant revenue drop to $0.2 million from $9.2 million in Q2 2020, primarily due to the cessation of product sales after the XERMELO divestiture. R&D expenses decreased to $10.3 million, while SG&A expenses fell to $7.9 million. The net loss improved to $18.1 million ($0.13 per share) compared to the prior year's loss of $69.1 million ($0.65 per share). The company anticipates filing a New Drug Application for sotagliflozin by year-end and reports increased enrollment in ongoing Phase 2 studies of LX9211.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will announce its second-quarter 2021 financial results on July 30, 2021, before market opening. A conference call is scheduled at 8:00 a.m. ET to discuss these results and provide a business update. The company is advancing drug candidates through its Genome5000™ program, which targets over 100 proteins for various diseases. Lexicon has one drug on the market and a pipeline focused on neuropathic pain, heart failure, and diabetes. For more details, visit lexpharma.com.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced a symposium on sotagliflozin during the American Diabetes Association’s 81st Scientific Sessions from June 25-29, 2021. The event will focus on updates from the SCORED and SOLOIST cardiovascular and kidney outcomes trials on June 29. Sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, is approved in the EU for adults with type 1 diabetes who struggle with glycemic control despite optimal insulin therapy, yet has not been commercially launched. This highlights Lexicon's commitment to advancing diabetes treatment.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that CEO Lonnel Coats will present at the 2021 Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:30 a.m. ET. A live webcast of the presentation will be accessible on Lexicon's website, with an archived version available for two weeks post-event.
Lexicon focuses on pioneering innovative medicines through its Genome5000™ program, having identified over 100 protein targets for various diseases. The company's portfolio includes drug candidates in clinical and preclinical development for conditions like neuropathic pain and diabetes.